{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:09:47Z","timestamp":1788768587852,"version":"build-2803163510"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"DOI":"10.1186\/s13395-026-00439-0","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:19:54Z","timestamp":1785165594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Duchenne muscular dystrophy: from gene to gene-ius therapies"],"prefix":"10.1186","volume":"16","author":[{"given":"Antoine","family":"Muchir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Musaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"439_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AEH Emery","year":"2002","unstructured":"Emery AEH. The muscular dystrophies. Lancet. 2002;359:687\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(02)07815-7.","journal-title":"Lancet"},{"key":"439_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM, Dystrophin. The protein product of the duchenne muscular dystrophy locus. Cell. 1987;51:919\u201328. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4.","journal-title":"Cell"},{"key":"439_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/JMEDGENET-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet. 2016;53:145\u201351. https:\/\/doi.org\/10.1136\/JMEDGENET-2015-103387.","journal-title":"J Med Genet"},{"key":"439_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6.","journal-title":"Lancet Neurol"},{"key":"439_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3.","journal-title":"Lancet Neurol"},{"key":"439_CR6","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D, Systemic AAV. Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Mol Therapy Cell Press. 2018;26:2337\u201356. https:\/\/doi.org\/10.1016\/j.ymthe.2018.07.011.","journal-title":"Mol Therapy Cell Press"},{"key":"439_CR7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s13311-023-01423-y","volume":"20","author":"ES D\u2019Ambrosio","year":"2023","unstructured":"D\u2019Ambrosio ES, Mendell JR. Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy. Neurother Springer Sci Bus Media Deutschland GmbH. 2023;20:1669\u201381. https:\/\/doi.org\/10.1007\/s13311-023-01423-y.","journal-title":"Neurother Springer Sci Bus Media Deutschland GmbH"},{"key":"439_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1083\/JCB.122.4.809","volume":"122","author":"JM Ervasti","year":"1993","unstructured":"Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol. 1993;122:809\u201323. https:\/\/doi.org\/10.1083\/JCB.122.4.809.","journal-title":"J Cell Biol"},{"key":"439_CR9","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/PNAS.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993;90:3710\u20134. https:\/\/doi.org\/10.1073\/PNAS.90.8.3710.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"439_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","volume":"53","author":"M Koenig","year":"1988","unstructured":"Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 1988;53:219\u201328. https:\/\/doi.org\/10.1016\/0092-8674(88)90383-2.","journal-title":"Cell"},{"key":"439_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/345315A0","volume":"345","author":"JM Ervasti","year":"1990","unstructured":"Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990;345:315\u20139. https:\/\/doi.org\/10.1038\/345315A0.","journal-title":"Nature"},{"key":"439_CR12","doi-asserted-by":"publisher","first-page":"1182524","DOI":"10.3389\/FCELL.2023.1182524","volume":"11","author":"V Mirouse","year":"2023","unstructured":"Mirouse V. Evolution and developmental functions of the dystrophin-associated protein complex: beyond the idea of a muscle-specific cell adhesion complex. Front Cell Dev Biol. 2023;11:1182524. https:\/\/doi.org\/10.3389\/FCELL.2023.1182524.","journal-title":"Front Cell Dev Biol"},{"key":"439_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/PHYSREV.00007.2015","volume":"96","author":"DG Allen","year":"2016","unstructured":"Allen DG, Whitehead NP, Froehner SC. Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. Physiol Rev. 2016;96:253\u2013305. https:\/\/doi.org\/10.1152\/PHYSREV.00007.2015.","journal-title":"Physiol Rev"},{"key":"439_CR14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/CELLS9051297","volume":"9","author":"L Forcina","year":"2020","unstructured":"Forcina L, Cosentino M, Musar\u00f2 A. Mechanisms Regulating Muscle Regeneration: Insights into the Interrelated and Time-Dependent Phases of Tissue Healing. Cells. 2020;9:1297. https:\/\/doi.org\/10.3390\/CELLS9051297.","journal-title":"Cells"},{"key":"439_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/J.STEM.2018.10.006","volume":"23","author":"P Feige","year":"2018","unstructured":"Feige P, Brun CE, Ritso M, Rudnicki MA. Orienting Muscle Stem Cells for Regeneration in Homeostasis, Aging, and Disease. Cell Stem Cell. 2018;23:653\u201364. https:\/\/doi.org\/10.1016\/J.STEM.2018.10.006.","journal-title":"Cell Stem Cell"},{"key":"439_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/J.CELL.2007.03.044","volume":"129","author":"S Kuang","year":"2007","unstructured":"Kuang S, Kuroda K, Le Grand F, Rudnicki MA. Asymmetric Self-Renewal and Commitment of Satellite Stem Cells in Muscle. Cell. 2007;129:999\u20131010. https:\/\/doi.org\/10.1016\/J.CELL.2007.03.044.","journal-title":"Cell"},{"key":"439_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/J.BBRC.2009.06.053","volume":"386","author":"M Onopiuk","year":"2009","unstructured":"Onopiuk M, Brutkowski W, Wierzbicka K, Wojciechowska S, Szczepanowska J, Fronk J, et al. Mutation in dystrophin-encoding gene affects energy metabolism in mouse myoblasts. Biochem Biophys Res Commun. 2009;386:463\u20136. https:\/\/doi.org\/10.1016\/J.BBRC.2009.06.053.","journal-title":"Biochem Biophys Res Commun"},{"key":"439_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/NM.3990","volume":"21","author":"NA Dumont","year":"2015","unstructured":"Dumont NA, Wang YX, Von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21:1455\u201363. https:\/\/doi.org\/10.1038\/NM.3990.","journal-title":"Nat Med"},{"key":"439_CR19","doi-asserted-by":"publisher","first-page":"1180980","DOI":"10.3389\/FPHYS.2023.1180980","volume":"14","author":"K Kodippili","year":"2023","unstructured":"Kodippili K, Rudnicki MA. Satellite cell contribution to disease pathology in Duchenne muscular dystrophy. Front Physiol. 2023;14:1180980. https:\/\/doi.org\/10.3389\/FPHYS.2023.1180980.","journal-title":"Front Physiol"},{"key":"439_CR20","doi-asserted-by":"publisher","unstructured":"Liu X, Wang H, Xu M, Wang H, Wang H, Fang W, et al. The role of the cGAS\/STING pathway in skeletal muscle regeneration: modulation of inflammation, macrophage polarization, and oxidative stress. Cell Mol Biol Lett. 2026;31. https:\/\/doi.org\/10.1186\/S11658-026-00908-W.","DOI":"10.1186\/S11658-026-00908-W"},{"key":"439_CR21","doi-asserted-by":"publisher","unstructured":"Rybalka E, Timpani CA, Cooke MB, Williams AD, Hayes A. Defects in mitochondrial ATP synthesis in dystrophin-deficient mdx skeletal muscles may be caused by complex I insufficiency. PLoS ONE. 2014;9. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0115763.","DOI":"10.1371\/JOURNAL.PONE.0115763"},{"key":"439_CR22","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1152\/JAPPLPHYSIOL.01145.2006","volume":"102","author":"JG Tidball","year":"2007","unstructured":"Tidball JG, Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol (1985). 2007;102:1677\u201386. https:\/\/doi.org\/10.1152\/JAPPLPHYSIOL.01145.2006.","journal-title":"J Appl Physiol (1985)"},{"key":"439_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/965631","author":"Y Kharraz","year":"2014","unstructured":"Kharraz Y, Guerra J, Pessina P, Serrano AL, Mu\u00f1oz-C\u00e1noves P. Understanding the process of fibrosis in Duchenne muscular dystrophy. Biomed Res Int. 2014. https:\/\/doi.org\/10.1155\/2014\/965631.","journal-title":"Biomed Res Int"},{"key":"439_CR24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1073\/PNAS.81.4.1189","volume":"81","author":"G Bulfield","year":"1984","unstructured":"Bulfield G, Siller WG, Wight PAL, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984;81:1189\u201392. https:\/\/doi.org\/10.1073\/PNAS.81.4.1189.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"439_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2008.03.008","volume":"31","author":"MD Grounds","year":"2008","unstructured":"Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008;31:1\u201319. https:\/\/doi.org\/10.1016\/j.nbd.2008.03.008.","journal-title":"Neurobiol Dis"},{"key":"439_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/J.1469-7793.2001.00591","volume":"535","author":"GS Lynch","year":"2001","unstructured":"Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6\u201328 months old. J Physiol. 2001;535:591\u2013600. https:\/\/doi.org\/10.1111\/J.1469-7793.2001.00591. .X;Wgroup:String:Publication.","journal-title":"J Physiol"},{"key":"439_CR27","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1096\/FJ.067353com","volume":"21","author":"JS Chamberlain","year":"2007","unstructured":"Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 2007;21:2195\u2013204. https:\/\/doi.org\/10.1096\/FJ.067353com.","journal-title":"FASEB J"},{"key":"439_CR28","doi-asserted-by":"publisher","unstructured":"Tasfaout H, McMillen TS, Reyes TR, Halbert CL, Tian R, Regnier M, et al. Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice. J Clin Invest. 2025;135. https:\/\/doi.org\/10.1172\/JCI189075.","DOI":"10.1172\/JCI189075"},{"key":"439_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.107.162982","volume":"102","author":"B Bostick","year":"2008","unstructured":"Bostick B, Yue Y, Long C, Duan D. Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin\/utrophin expression. Circ Res. 2008;102:121\u201330. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.162982.","journal-title":"Circ Res"},{"key":"439_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/AR.1092420109","volume":"242","author":"JP Lefaucheur","year":"1995","unstructured":"Lefaucheur JP, Pastoret C, Sebille A. Phenotype of dystrophinopathy in old mdx mice. Anat Rec. 1995;242:70\u20136. https:\/\/doi.org\/10.1002\/AR.1092420109.","journal-title":"Anat Rec"},{"key":"439_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0022-510X(94)00276-T","volume":"129","author":"C Pastoret","year":"1995","unstructured":"Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci. 1995;129:97\u2013105. https:\/\/doi.org\/10.1016\/0022-510X(94)00276-T.","journal-title":"J Neurol Sci"},{"key":"439_CR32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1006\/bbrc.1997.7328","volume":"238","author":"E Araki","year":"1997","unstructured":"Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I, et al. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in duchenne muscular dystrophy. Biochem Biophys Res Commun. 1997;238:492\u20137. https:\/\/doi.org\/10.1006\/bbrc.1997.7328.","journal-title":"Biochem Biophys Res Commun"},{"key":"439_CR33","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/HMG\/5.8.1149","volume":"5","author":"W Im","year":"1996","unstructured":"Im W, Bin, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet. 1996;5:1149\u201353. https:\/\/doi.org\/10.1093\/HMG\/5.8.1149.","journal-title":"Hum Mol Genet"},{"key":"439_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cell.2010.11.039","volume":"143","author":"A Sacco","year":"2010","unstructured":"Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, et al. Short telomeres and stem cell exhaustion model duchenne muscular dystrophy in mdx\/mTR mice. Cell Elsevier B V. 2010;143:1059\u201371. https:\/\/doi.org\/10.1016\/j.cell.2010.11.039.","journal-title":"Cell Elsevier B V"},{"key":"439_CR35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0092-8674(00)80533-4","volume":"90","author":"RM Grady","year":"1997","unstructured":"Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanest JR. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell Elsevier B V. 1997;90:729\u201338. https:\/\/doi.org\/10.1016\/S0092-8674(00)80533-4.","journal-title":"Cell Elsevier B V"},{"key":"439_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.omtm.2017.06.006","volume":"6","author":"CH Hakim","year":"2017","unstructured":"Hakim CH, Wasala NB, Pan X, Kodippili K, Yue Y, Zhang K, et al. A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA\/2J-mdx Model of Duchenne Muscular Dystrophy. Mol Ther Methods Clin Dev. 2017;6:216\u201330. https:\/\/doi.org\/10.1016\/j.omtm.2017.06.006.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"439_CR37","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.2353\/ajpath.2010.090887","volume":"176","author":"SI Fukada","year":"2010","unstructured":"Fukada SI, Morikawa D, Yamamoto Y, Yoshida T, Sumie N, Yamaguchi M, et al. Genetic background affects properties of satellite cells and mdx phenotypes. Am J Pathol. 2010;176:2414\u201324. https:\/\/doi.org\/10.2353\/ajpath.2010.090887.","journal-title":"Am J Pathol"},{"key":"439_CR38","doi-asserted-by":"publisher","unstructured":"Yucel N, Chang AC, Day JW, Rosenthal N, Blau HM. Humanizing the mdx mouse model of DMD: the long and the short of it. NPJ Regen Med. 2018;3. https:\/\/doi.org\/10.1038\/S41536-018-0045-4.","DOI":"10.1038\/S41536-018-0045-4"},{"key":"439_CR39","doi-asserted-by":"publisher","first-page":"13120","DOI":"10.1073\/PNAS.1615340113","volume":"113","author":"ACY Chang","year":"2016","unstructured":"Chang ACY, Ong SG, LaGory EL, Kraft PE, Giaccia AJ, Wu JC, et al. Telomere shortening and metabolic compromise underlie dystrophic cardiomyopathy. Proc Natl Acad Sci U S A. 2016;113:13120\u20135. https:\/\/doi.org\/10.1073\/PNAS.1615340113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"439_CR40","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/NCB2790","volume":"15","author":"F Mourkioti","year":"2013","unstructured":"Mourkioti F, Kustan J, Kraft P, Day JW, Zhao MM, Kost-Alimova M, et al. Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat Cell Biol. 2013;15:895\u2013904. https:\/\/doi.org\/10.1038\/NCB2790.","journal-title":"Nat Cell Biol"},{"key":"439_CR41","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/HMG\/DDL018","volume":"15","author":"C Guo","year":"2006","unstructured":"Guo C, Willem M, Werner A, Raivich G, Emerson M, Neyses L, et al. Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet. 2006;15:989\u201398. https:\/\/doi.org\/10.1093\/HMG\/DDL018.","journal-title":"Hum Mol Genet"},{"key":"439_CR42","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1101\/GAD.10.10.1173","volume":"10","author":"LA Megeney","year":"1996","unstructured":"Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA. MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 1996;10:1173\u201383. https:\/\/doi.org\/10.1101\/GAD.10.10.1173.","journal-title":"Genes Dev"},{"key":"439_CR43","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1073\/PNAS.96.1.220","volume":"96","author":"LA Megeney","year":"1999","unstructured":"Megeney LA, Kablar B, Perry RLS, Ying C, May L, Rudnicki MA. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci U S A. 1999;96:220\u20135. https:\/\/doi.org\/10.1073\/PNAS.96.1.220.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"439_CR44","doi-asserted-by":"publisher","unstructured":"Chandrasekharan K, Yoon JH, Xu Y, DeVries S, Camboni M, Janssen PML, et al. A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Transl Med. 2010;2. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3000692.","DOI":"10.1126\/SCITRANSLMED.3000692"},{"key":"439_CR45","doi-asserted-by":"publisher","unstructured":"Relaix F, Lafuste P, Taglietti V, Tiret L. The rise of rat models for Duchenne muscular dystrophy and therapeutic evaluations. Skelet Muscle. 2025;15. https:\/\/doi.org\/10.1186\/S13395-025-00395-1.","DOI":"10.1186\/S13395-025-00395-1"},{"key":"439_CR46","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/srep01420","volume":"3","author":"S Carosio","year":"2013","unstructured":"Carosio S, Barberi L, Rizzuto E, Nicoletti C, Prete Z, Del, Musar\u00f2 A. Generation of eX vivo-vascularized Muscle Engineered Tissue (X-MET). Sci Rep. 2013;3:1420. https:\/\/doi.org\/10.1038\/srep01420.","journal-title":"Sci Rep"},{"key":"439_CR47","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/TEN.TEA.2012.0761","volume":"20","author":"BT Corona","year":"2014","unstructured":"Corona BT, Ward CL, Baker HB, Walters TJ, Christ GJ. Implantation of in vitro tissue engineered muscle repair constructs and bladder acellular matrices partially restore in vivo skeletal muscle function in a rat model of volumetric muscle loss injury. Tissue Eng Part A. 2014;20:705\u201315. https:\/\/doi.org\/10.1089\/TEN.TEA.2012.0761.","journal-title":"Tissue Eng Part A"},{"key":"439_CR48","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1089\/TEN.TEA.2010.0682","volume":"17","author":"MA MacHingal","year":"2011","unstructured":"MacHingal MA, Corona BT, Walters TJ, Kesireddy V, Koval CN, Dannahower A, et al. A tissue-engineered muscle repair construct for functional restoration of an irrecoverable muscle injury in a murine model. Tissue Eng Part A. 2011;17:2291\u2013303. https:\/\/doi.org\/10.1089\/TEN.TEA.2010.0682.","journal-title":"Tissue Eng Part A"},{"key":"439_CR49","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1073\/PNAS.1402723111","volume":"111","author":"M Juhas","year":"2014","unstructured":"Juhas M, Engelmayr GC, Fontanella AN, Palmer GM, Bursac N. Biomimetic engineered muscle with capacity for vascular integration and functional maturation in vivo. Proc Natl Acad Sci U S A. 2014;111:5508\u201313. https:\/\/doi.org\/10.1073\/PNAS.1402723111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"439_CR50","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.1073\/PNAS.1402679111","volume":"111","author":"Y Shandalov","year":"2014","unstructured":"Shandalov Y, Egozi D, Koffler J, Dado-Rosenfeld D, Ben-Shimol D, Freiman A, et al. An engineered muscle flap for reconstruction of large soft tissue defects. Proc Natl Acad Sci U S A. 2014;111:6010\u20135. https:\/\/doi.org\/10.1073\/PNAS.1402679111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"439_CR51","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1089\/TEN.TEA.2014.0060","volume":"20","author":"KW Vandusen","year":"2014","unstructured":"Vandusen KW, Syverud BC, Williams ML, Lee JD, Larkin LM. Engineered skeletal muscle units for repair of volumetric muscle loss in the tibialis anterior muscle of a rat. Tissue Eng Part A. 2014;20:2920\u201330. https:\/\/doi.org\/10.1089\/TEN.TEA.2014.0060.","journal-title":"Tissue Eng Part A"},{"key":"439_CR52","doi-asserted-by":"publisher","unstructured":"Zouhair M, Cosentino M, Apa L, Genovese D, Di Iorio SMM, Nicoletti C, et al. A 3D skeletal muscle system for disease modelling and secretome profiling of Duchenne muscular dystrophy. Skelet Muscle. 2026;16. https:\/\/doi.org\/10.1186\/S13395-026-00423-8.","DOI":"10.1186\/S13395-026-00423-8"},{"key":"439_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.15252\/EMMM.201404062","volume":"7","author":"C Fuoco","year":"2015","unstructured":"Fuoco C, Rizzi R, Biondo A, Longa E, Mascaro A, Shapira-Schweitzer K, et al. In vivo generation of a mature and functional artificial skeletal muscle. EMBO Mol Med. 2015;7:411\u201322. https:\/\/doi.org\/10.15252\/EMMM.201404062.","journal-title":"EMBO Mol Med"},{"key":"439_CR54","doi-asserted-by":"publisher","unstructured":"Madden L, Juhas M, Kraus WE, Truskey GA, Bursac N. Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. Elife. 2015;4. https:\/\/doi.org\/10.7554\/ELIFE.04885.","DOI":"10.7554\/ELIFE.04885"},{"key":"439_CR55","doi-asserted-by":"publisher","unstructured":"Quarta M, Cromie M, Chacon R, Blonigan J, Garcia V, Akimenko I, et al. Bioengineered constructs combined with exercise enhance stem cell-mediated treatment of volumetric muscle loss. Nat Commun. 2017;8. https:\/\/doi.org\/10.1038\/NCOMMS15613.","DOI":"10.1038\/NCOMMS15613"},{"key":"439_CR56","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.celrep.2018.03.091","volume":"23","author":"SM Maffioletti","year":"2018","unstructured":"Maffioletti SM, Sarcar S, Henderson ABH, Mannhardt I, Pinton L, Moyle LA, et al. Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering. Cell Rep. 2018;23:899\u2013908. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.091.","journal-title":"Cell Rep"},{"key":"439_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JND-210776","volume":"9","author":"WD Biggar","year":"2022","unstructured":"Biggar WD, Skalsky A, McDonald CM. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2022;9:463\u201376. https:\/\/doi.org\/10.3233\/JND-210776.","journal-title":"J Neuromuscul Dis"},{"key":"439_CR58","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123\u201331. https:\/\/doi.org\/10.1212\/WNL.0000000000003217.","journal-title":"Neurology"},{"key":"439_CR59","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/MUS.26736","volume":"61","author":"CM McDonald","year":"2020","unstructured":"McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2020;61:26\u201335. https:\/\/doi.org\/10.1002\/MUS.26736.","journal-title":"Muscle Nerve"},{"key":"439_CR60","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/JAMANEUROL.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, et al. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Neurol. 2022;79:1005\u201314. https:\/\/doi.org\/10.1001\/JAMANEUROL.2022.2480.","journal-title":"JAMA Neurol"},{"key":"439_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/HMG\/DDAD173","volume":"33","author":"G Liu","year":"2024","unstructured":"Liu G, Lipari P, Mollin A, Jung S, Teplova I, Li W, et al. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models. Hum Mol Genet. 2024;33:211\u201323. https:\/\/doi.org\/10.1093\/HMG\/DDAD173.","journal-title":"Hum Mol Genet"},{"key":"439_CR62","doi-asserted-by":"publisher","unstructured":"Anjum AF, Anjum MB, Rehman R. ur. Unleashing the Potential of Givinostat: A Novel Therapy for Duchenne Muscular Dystrophy. Curr Ther Res Clin Exp. 2025;102. https:\/\/doi.org\/10.1016\/j.curtheres.2025.100787.","DOI":"10.1016\/j.curtheres.2025.100787"},{"key":"439_CR63","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1016\/J.CELL.2026.05.030","volume":"189","author":"W Guo","year":"2026","unstructured":"Guo W, Tang H, Yi Z, Zhang T, Yuan P, Wang C, et al. Long-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humans. Cell. 2026;189:4377\u2013e439520. https:\/\/doi.org\/10.1016\/J.CELL.2026.05.030.","journal-title":"Cell"},{"key":"439_CR64","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.ymthe.2025.03.065","volume":"33","author":"NE Bengtsson","year":"2025","unstructured":"Bengtsson NE, Tasfaout H, Chamberlain JS. The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy. Mol Ther. 2025;33:2035\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.065.","journal-title":"Mol Ther"},{"key":"439_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ymthe.2025.10.007","volume":"34","author":"DJ Keselman","year":"2026","unstructured":"Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, et al. Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns. Mol Ther. 2026;34:123\u201330. https:\/\/doi.org\/10.1016\/j.ymthe.2025.10.007.","journal-title":"Mol Ther"},{"key":"439_CR66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ymthe.2025.12.020","volume":"34","author":"JM Crudele","year":"2026","unstructured":"Crudele JM. Safety and efficacy of commercially administered elevidys (delandistrogene moxeparvovec-rokl). Mol Ther. 2026;34:10\u20131. https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.020.","journal-title":"Mol Ther"},{"key":"439_CR67","unstructured":"Issue. Molecular Therapy. https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/issue?pii=S1525-0016(25)X0005-8. Accessed 1 Jul 2026."},{"key":"439_CR68","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/HUM.2023.053","volume":"34","author":"F Chemello","year":"2023","unstructured":"Chemello F, Olson EN, Bassel-Duby R. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy. Hum Gene Ther. 2023;34:379\u201387. https:\/\/doi.org\/10.1089\/HUM.2023.053.","journal-title":"Hum Gene Ther"},{"key":"439_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/NCOMMS7244","volume":"6","author":"DG Ousterout","year":"2015","unstructured":"Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun. 2015;6:1\u201313. https:\/\/doi.org\/10.1038\/NCOMMS7244.","journal-title":"Nat Commun"},{"key":"439_CR70","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, et al. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell. 2016;18:533\u201340. https:\/\/doi.org\/10.1016\/j.stem.2016.01.021.","journal-title":"Cell Stem Cell"},{"key":"439_CR71","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.stemcr.2023.07.007","volume":"18","author":"Y Kita","year":"2023","unstructured":"Kita Y, Okuzaki Y, Naoe Y, Lee J, Bang U, Okawa N, et al. Dual CRISPR-Cas3 system for inducing multi-exon skipping in DMD patient-derived iPSCs. Stem Cell Rep. 2023;18:1753\u201365. https:\/\/doi.org\/10.1016\/j.stemcr.2023.07.007.","journal-title":"Stem Cell Rep"},{"key":"439_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/S41591-019-0344-3","volume":"25","author":"CE Nelson","year":"2019","unstructured":"Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019;25:427\u201332. https:\/\/doi.org\/10.1038\/S41591-019-0344-3.","journal-title":"Nat Med"},{"key":"439_CR73","doi-asserted-by":"publisher","first-page":"14038","DOI":"10.1038\/mtm.2014.38","volume":"1","author":"AL Arnett","year":"2014","unstructured":"Arnett AL, Konieczny P, Ramos JN, Hall J, Odom G, Yablonka-Reuveni Z, et al. Adeno-associated viral vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev. 2014;1:14038. https:\/\/doi.org\/10.1038\/mtm.2014.38.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"439_CR74","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.ymthe.2020.11.003","volume":"29","author":"NE Bengtsson","year":"2021","unstructured":"Bengtsson NE, Tasfaout H, Hauschka SD, Chamberlain JS. Dystrophin Gene-Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles. Mol Ther. 2021;29:1070\u201385. https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.003.","journal-title":"Mol Ther"},{"key":"439_CR75","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/S41586-024-07710-8","volume":"632","author":"H Tasfaout","year":"2024","unstructured":"Tasfaout H, Halbert CL, McMillen TS, Allen JM, Reyes TR, Flint GV, et al. Split intein-mediated protein trans-splicing to express large dystrophins. Nature. 2024;632:192\u2013200. https:\/\/doi.org\/10.1038\/S41586-024-07710-8.","journal-title":"Nature"},{"key":"439_CR76","doi-asserted-by":"publisher","unstructured":"Zhou Y, Zhang C, Xiao W, Herzog RW, Han R. Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice. Nat Commun. 2024;15. https:\/\/doi.org\/10.1038\/S41467-024-50569-6.","DOI":"10.1038\/S41467-024-50569-6"},{"key":"439_CR77","unstructured":"2026 Abstract Library - MDA Clinical & Scientific Conference. 2026. https:\/\/www.mdaconference.org\/abstracts\/2026-abstract-library\/. Accessed 1 Jul 2026."},{"key":"439_CR78","unstructured":"RNA End-Joining | Insmed. https:\/\/insmed.com\/science\/areas-of-innovation\/rna-end-joining\/. Accessed 1 Jul 2026."},{"key":"439_CR79","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nm0302-253","volume":"8","author":"SQ Harper","year":"2002","unstructured":"Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8:253\u201361. https:\/\/doi.org\/10.1038\/nm0302-253.","journal-title":"Nat Med"},{"key":"439_CR80","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-61779-370-7_5","volume":"807","author":"C Qiao","year":"2011","unstructured":"Qiao C, Koo T, Li J, Xiao X, Dickson JG. Gene therapy in skeletal muscle mediated by adeno-associated virus vectors. Methods Mol Biol. 2011;807:119\u201340. https:\/\/doi.org\/10.1007\/978-1-61779-370-7_5.","journal-title":"Methods Mol Biol"},{"key":"439_CR81","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1016\/j.ymthe.2025.08.029","volume":"33","author":"JS Chamberlain","year":"2025","unstructured":"Chamberlain JS, Davidson BL, George LA, Byrne BJ, Barrett D. The future of gene therapy: Safer vectors, sharper focus: High-profile failures demand deep root cause analysis \u2014 but the transformative potential of AAV remains within reach if the field is willing to learn and evolve. Mol Ther. 2025;33:4694\u20135. https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.029.","journal-title":"Mol Ther"},{"key":"439_CR82","doi-asserted-by":"publisher","unstructured":"Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188. https:\/\/doi.org\/10.1016\/j.addr.2022.114416.","DOI":"10.1016\/j.addr.2022.114416"},{"key":"439_CR83","doi-asserted-by":"publisher","first-page":"116695","DOI":"10.1016\/j.celrep.2025.116695","volume":"45","author":"T Mochida","year":"2026","unstructured":"Mochida T, Fujimoto N, Asahina M, Asano S, Araki S, Inukai N, et al. Muscle satellite cell editing by LNP-CRISPR-Cas9 to resist muscle injury. Cell Rep. 2026;45:116695. https:\/\/doi.org\/10.1016\/j.celrep.2025.116695.","journal-title":"Cell Rep"},{"key":"439_CR84","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0960-8966(02)00076-7","volume":"12","author":"T Partridge","year":"2002","unstructured":"Partridge T. Myoblast transplantation. Neuromuscul Disord. 2002;12:S3. https:\/\/doi.org\/10.1016\/S0960-8966(02)00076-7.","journal-title":"Neuromuscul Disord"},{"key":"439_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CRITREVEUKARYOTGENEEXPR.2015011074","volume":"25","author":"A Bajek","year":"2015","unstructured":"Bajek A, Porowinska D, Kloskowski T, Brzoska E, Ciemerych MA, Drewa T. Cell therapy in Duchenne muscular dystrophy treatment: clinical trials overview. Crit Rev Eukaryot Gene Expr. 2015;25:1\u201311. https:\/\/doi.org\/10.1615\/CRITREVEUKARYOTGENEEXPR.2015011074.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"439_CR86","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1056\/NEJM199509283331303","volume":"333","author":"JR Mendell","year":"1995","unstructured":"Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, et al. Myoblast transfer in the treatment of Duchenne\u2019s muscular dystrophy. N Engl J Med. 1995;333:832\u20138. https:\/\/doi.org\/10.1056\/NEJM199509283331303.","journal-title":"N Engl J Med"},{"key":"439_CR87","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/ART.38985","volume":"67","author":"C Sciorati","year":"2015","unstructured":"Sciorati C, Monno A, Ascherman DP, Seletti E, Manfredi AA, Rovere-Querini P. Required role of apoptotic myogenic precursors and toll-like receptor stimulation for the establishment of autoimmune myositis in experimental murine models. Arthritis Rheumatol. 2015;67:809\u201322. https:\/\/doi.org\/10.1002\/ART.38985.","journal-title":"Arthritis Rheumatol"},{"key":"439_CR88","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.scr.2016.03.005","volume":"16","author":"G Cossu","year":"2016","unstructured":"Cossu G, Buccione R, De Luca M. A discussion on cell therapy in Manchester. Stem Cell Res. 2016;16:614\u20136. https:\/\/doi.org\/10.1016\/j.scr.2016.03.005.","journal-title":"Stem Cell Res"},{"key":"439_CR89","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/J.MOLMED.2019.07.004","volume":"25","author":"S Selvaraj","year":"2019","unstructured":"Selvaraj S, Kyba M, Perlingeiro RCR. Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies. Trends Mol Med. 2019;25:803\u201316. https:\/\/doi.org\/10.1016\/J.MOLMED.2019.07.004.","journal-title":"Trends Mol Med"},{"key":"439_CR90","doi-asserted-by":"publisher","unstructured":"Tedesco FS, Gerli MFM, Perani L, Benedetti S, Ungaro F, Cassano M, et al. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med. 2012;4. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3003541.","DOI":"10.1126\/SCITRANSLMED.3003541"},{"key":"439_CR91","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1172\/JCI82735","volume":"125","author":"M Quattrocelli","year":"2015","unstructured":"Quattrocelli M, Swinnen M, Giacomazzi G, Camps J, Barth\u00e9lemy I, Ceccarelli G, et al. Mesodermal iPSC-derived progenitor cells functionally regenerate cardiac and skeletal muscle. J Clin Invest. 2015;125:4463\u201382. https:\/\/doi.org\/10.1172\/JCI82735.","journal-title":"J Clin Invest"},{"key":"439_CR92","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.stem.2012.02.015","volume":"10","author":"R Darabi","year":"2012","unstructured":"Darabi R, Arpke RW, Irion S, Dimos JT, Grskovic M, Kyba M, et al. Human ES- and iPS-derived myogenic progenitors restore dystrophin and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell. 2012;10:610\u20139. https:\/\/doi.org\/10.1016\/j.stem.2012.02.015.","journal-title":"Cell Stem Cell"},{"key":"439_CR93","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/S12015-011-9258-2","volume":"7","author":"R Darabi","year":"2011","unstructured":"Darabi R, Pan W, Bosnakovski D, Baik J, Kyba M, Perlingeiro RCR. Functional myogenic engraftment from mouse iPS cells. Stem Cell Rev Rep. 2011;7:948\u201357. https:\/\/doi.org\/10.1007\/S12015-011-9258-2.","journal-title":"Stem Cell Rev Rep"},{"key":"439_CR94","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/mt.2012.188","volume":"20","author":"S Goudenege","year":"2012","unstructured":"Goudenege S, Lebel C, Huot NB, Dufour C, Fujii I, Gekas J, et al. Myoblasts derived from normal hESCs and dystrophic hipscs efficiently fuse with existing muscle fibers following transplantation. Mol Ther. 2012;20:2153\u201367. https:\/\/doi.org\/10.1038\/mt.2012.188.","journal-title":"Mol Ther"},{"key":"439_CR95","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5966\/SCTM.2013-0143","volume":"3","author":"T Hosoyama","year":"2014","unstructured":"Hosoyama T, McGivern JV, Van Dyke JM, Ebert AD, Suzuki M. Derivation of myogenic progenitors directly from human pluripotent stem cells using a sphere-based culture. Stem Cells Transl Med. 2014;3:564\u201374. https:\/\/doi.org\/10.5966\/SCTM.2013-0143.","journal-title":"Stem Cells Transl Med"},{"key":"439_CR96","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.stemcr.2013.10.007","volume":"1","author":"B Borchin","year":"2013","unstructured":"Borchin B, Chen J, Barberi T. Derivation and FACS-mediated purification of PAX3+\/PAX7\u2009+\u2009skeletal muscle precursors from human pluripotent stem cells. Stem Cell Rep. 2013;1:620\u201331. https:\/\/doi.org\/10.1016\/j.stemcr.2013.10.007.","journal-title":"Stem Cell Rep"},{"key":"439_CR97","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1073\/PNAS.80.15.4856","volume":"80","author":"HM Blau","year":"1983","unstructured":"Blau HM, Webster C, Pavlath GK. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 1983;80:4856\u201360. https:\/\/doi.org\/10.1073\/PNAS.80.15.4856. ;Issue:Issue:doi.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"439_CR98","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/S40478-023-01657-Z","volume":"11","author":"N Cardone","year":"2023","unstructured":"Cardone N, Taglietti V, Baratto S, Kefi K, Periou B, Gitiaux C, et al. Myopathologic trajectory in Duchenne muscular dystrophy (DMD) reveals lack of regeneration due to senescence in satellite cells. Acta Neuropathol Commun. 2023;11:167\u2013. https:\/\/doi.org\/10.1186\/S40478-023-01657-Z.","journal-title":"Acta Neuropathol Commun"},{"key":"439_CR99","doi-asserted-by":"publisher","first-page":"16385","DOI":"10.1038\/s41598-020-73315-6","volume":"10","author":"H Sugihara","year":"2020","unstructured":"Sugihara H, Teramoto N, Nakamura K, Shiga T, Shirakawa T, Matsuo M, et al. Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy. Sci Rep. 2020;10:16385. https:\/\/doi.org\/10.1038\/s41598-020-73315-6.","journal-title":"Sci Rep"},{"key":"439_CR100","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/S13395-026-00426-5","volume":"16","author":"A Calls-Cobos","year":"2026","unstructured":"Calls-Cobos A, Be\u00e0 T\u00e0rrega A, Cisneros A, Rommelfanger M, Campanario S, Grima-Terr\u00e9n M, et al. Senescence dynamics define therapeutic windows for Duchenne muscular dystrophy in DBA\/2-mdx mice. Skelet Muscle. 2026;16:27. https:\/\/doi.org\/10.1186\/S13395-026-00426-5.","journal-title":"Skelet Muscle"},{"key":"439_CR101","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/npjregenmed.2016.6","volume":"1","author":"NA Dumont","year":"2016","unstructured":"Dumont NA, Rudnicki MA. Targeting muscle stem cell intrinsic defects to treat Duchenne muscular dystrophy. Regen Med. 2016;1:16006. https:\/\/doi.org\/10.1038\/npjregenmed.2016.6.","journal-title":"Regen Med"},{"key":"439_CR102","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/J.STEM.2019.01.002","volume":"24","author":"YX Wang","year":"2019","unstructured":"Wang YX, Feige P, Brun CE, Hekmatnejad B, Dumont NA, Renaud JM, et al. EGFR-Aurka Signaling Rescues Polarity and Regeneration Defects in Dystrophin-Deficient Muscle Stem Cells by Increasing Asymmetric Divisions. Cell Stem Cell. 2019;24:419\u2013e4326. https:\/\/doi.org\/10.1016\/J.STEM.2019.01.002.","journal-title":"Cell Stem Cell"},{"key":"439_CR103","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/J.STEMCR.2021.12.003","volume":"17","author":"SA Domenig","year":"2022","unstructured":"Domenig SA, Bundschuh N, Lenardi\u010d A, Ghosh A, Kim I, Qabrati X, et al. CRISPR\/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy. Stem Cell Rep. 2022;17:321\u201336. https:\/\/doi.org\/10.1016\/J.STEMCR.2021.12.003.","journal-title":"Stem Cell Rep"},{"key":"439_CR104","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/J.1750-3639.1996.TB00781.X","volume":"6","author":"DJ Blake","year":"1996","unstructured":"Blake DJ, Tinsley JM, Davies KE. Utrophin: a structural and functional comparison to dystrophin. Brain Pathol. 1996;6:37\u201347. https:\/\/doi.org\/10.1111\/J.1750-3639.1996.TB00781.X.","journal-title":"Brain Pathol"},{"key":"439_CR105","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/360591A0","volume":"360","author":"JM Tinsley","year":"1992","unstructured":"Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, Byth BC, et al. Primary structure of dystrophin-related protein. Nature. 1992;360:591\u20133. https:\/\/doi.org\/10.1038\/360591A0.","journal-title":"Nature"},{"key":"439_CR106","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","volume":"22","author":"TC Roberts","year":"2023","unstructured":"Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discovery. 2023;22:917\u201334. https:\/\/doi.org\/10.1038\/s41573-023-00775-6.","journal-title":"Nat Rev Drug Discovery"},{"key":"439_CR107","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0165-3806(99)00165-0","volume":"119","author":"S Lin","year":"2000","unstructured":"Lin S, Burgunder JM. Utrophin may be a precursor of dystrophin during skeletal muscle development. Dev Brain Res. 2000;119:289\u201395. https:\/\/doi.org\/10.1016\/S0165-3806(99)00165-0.","journal-title":"Dev Brain Res"},{"key":"439_CR108","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1093\/HMG\/DDV381","volume":"24","author":"TC Roberts","year":"2015","unstructured":"Roberts TC, Johansson HJ, McClorey G, Godfrey C, Blomberg EKM, Coursindel T, et al. Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Hum Mol Genet. 2015;24:6756\u201368. https:\/\/doi.org\/10.1093\/HMG\/DDV381.","journal-title":"Hum Mol Genet"},{"key":"439_CR109","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1074\/mcp.RA120.002345","volume":"19","author":"TLE van Westering","year":"2020","unstructured":"van Westering TLE, Johansson HJ, Hanson B, Coenen-Stass AML, Lomonosova Y, Tanihata J, et al. Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy. Mol Cell Proteomics. 2020;19:2047\u201367. https:\/\/doi.org\/10.1074\/mcp.RA120.002345.","journal-title":"Mol Cell Proteomics"},{"key":"439_CR110","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/JAMANEUROL.2013.4908","volume":"71","author":"K Anthony","year":"2014","unstructured":"Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N, et al. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. JAMA Neurol. 2014;71:32\u201340. https:\/\/doi.org\/10.1001\/JAMANEUROL.2013.4908.","journal-title":"JAMA Neurol"},{"key":"439_CR111","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(00)80532-2","volume":"90","author":"AE Deconinck","year":"1997","unstructured":"Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 1997;90:717\u201327. https:\/\/doi.org\/10.1016\/S0092-8674(00)80532-2.","journal-title":"Cell"},{"key":"439_CR112","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","volume":"4","author":"J Tinsley","year":"1998","unstructured":"Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med. 1998;4:1441\u20134. https:\/\/doi.org\/10.1038\/4033.","journal-title":"Nat Med"},{"key":"439_CR113","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1093\/HMG\/11.26.3333","volume":"11","author":"S Squire","year":"2002","unstructured":"Squire S, Raymackers JM, Vandebrouck C, Potter A, Tinsley J, Fisher R, et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet. 2002;11:3333\u201344. https:\/\/doi.org\/10.1093\/HMG\/11.26.3333.","journal-title":"Hum Mol Genet"},{"key":"439_CR114","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1021\/JM200135Z","volume":"54","author":"DR Chancellor","year":"2011","unstructured":"Chancellor DR, Davies KE, De Moor O, Dorgan CR, Johnson PD, Lambert AG, et al. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J Med Chem. 2011;54:3241\u201350. https:\/\/doi.org\/10.1021\/JM200135Z.","journal-title":"J Med Chem"},{"key":"439_CR115","doi-asserted-by":"publisher","unstructured":"Tinsley JM, Fairclough RJ, Storer R, Wilkes FJ, Potter AC, Squire SE, et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE. 2011;6. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0019189.","DOI":"10.1371\/JOURNAL.PONE.0019189"},{"key":"439_CR116","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/CPDD.642","volume":"8","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Tejura B, Spinty S, Roper H, Hughes I, Layton G, et al. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet. Clin Pharmacol Drug Dev. 2019;8:922\u201333. https:\/\/doi.org\/10.1002\/CPDD.642.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"439_CR117","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/ANIE.201912392","volume":"59","author":"IVL Wilkinson","year":"2020","unstructured":"Wilkinson IVL, Perkins KJ, Dugdale H, Moir L, Vuorinen A, Chatzopoulou M, et al. Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid. Angew Chem Int Ed Engl. 2020;59:2420\u20138. https:\/\/doi.org\/10.1002\/ANIE.201912392.","journal-title":"Angew Chem Int Ed Engl"},{"key":"439_CR118","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1093\/HMG\/DDV154","volume":"24","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Squire SE, Edwards B, Chen H, Burns DT, Shah N, et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet. 2015;24:4212\u201324. https:\/\/doi.org\/10.1093\/HMG\/DDV154.","journal-title":"Hum Mol Genet"},{"key":"439_CR119","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbadis.2018.01.030","volume":"1864","author":"C Pisani","year":"2018","unstructured":"Pisani C, Strimpakos G, Gabanella F, Di Certo MG, Onori A, Severini C, et al. Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1172\u201382. https:\/\/doi.org\/10.1016\/j.bbadis.2018.01.030.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"439_CR120","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.cell.2017.10.025","volume":"171","author":"HK Liao","year":"2017","unstructured":"Liao HK, Hatanaka F, Araoka T, Reddy P, Wu MZ, Sui Y, et al. In Vivo Target Gene Activation via CRISPR\/Cas9-Mediated Trans-epigenetic Modulation. Cell. 2017;171:1495\u2013e150715. https:\/\/doi.org\/10.1016\/j.cell.2017.10.025.","journal-title":"Cell"},{"key":"439_CR121","doi-asserted-by":"publisher","unstructured":"Basu U, Lozynska O, Moorwood C, Patel G, Wilton SD, Khurana TS. Translational regulation of utrophin by miRNAs. PLoS ONE. 2011;6. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0029376.","DOI":"10.1371\/JOURNAL.PONE.0029376"},{"key":"439_CR122","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.omtn.2020.08.031","volume":"22","author":"K Sengupta","year":"2020","unstructured":"Sengupta K, Mishra MK, Loro E, Spencer MJ, Pyle AD, Khurana TS. Genome Editing-Mediated Utrophin Upregulation in Duchenne Muscular Dystrophy Stem Cells. Mol Ther Nucleic Acids. 2020;22:500\u20139. https:\/\/doi.org\/10.1016\/j.omtn.2020.08.031.","journal-title":"Mol Ther Nucleic Acids"},{"key":"439_CR123","doi-asserted-by":"publisher","unstructured":"Andrysiak K, Ferdek PE, Sanetra AM, Machaj G, Schmidt L, Kraszewska I, et al. Upregulation of utrophin improves the phenotype of Duchenne muscular dystrophy hiPSC-derived CMs. Mol Ther Nucleic Acids. 2024;35. https:\/\/doi.org\/10.1016\/j.omtn.2024.102247.","DOI":"10.1016\/j.omtn.2024.102247"},{"key":"439_CR124","doi-asserted-by":"publisher","unstructured":"Wu R, Li P, Xiao P, Zhang S, Wang X, Liu J, et al. Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy. Nat Commun. 2025;16. https:\/\/doi.org\/10.1038\/S41467-025-57831-5.","DOI":"10.1038\/S41467-025-57831-5"},{"key":"439_CR125","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1242\/JCS.064808","volume":"123","author":"D Li","year":"2010","unstructured":"Li D, Bareja A, Judge L, Yue Y, Lai Y, Fairclough R, et al. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J Cell Sci. 2010;123:2008\u201313. https:\/\/doi.org\/10.1242\/JCS.064808.","journal-title":"J Cell Sci"},{"key":"439_CR126","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1073\/PNAS.1323842111","volume":"111","author":"JJ Belanto","year":"2014","unstructured":"Belanto JJ, Mader TL, Eckhoff MD, Strandjord DM, Banks GB, Gardner MK, et al. Microtubule binding distinguishes dystrophin from utrophin. Proc Natl Acad Sci U S A. 2014;111:5723\u20138. https:\/\/doi.org\/10.1073\/PNAS.1323842111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"439_CR127","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ebiom.2015.02.014","volume":"2","author":"L Pelosi","year":"2015","unstructured":"Pelosi L, Berardinelli MG, De Pasquale L, Nicoletti C, D\u2019Amico A, Carvello F, et al. Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade. EBioMedicine. 2015;2:285\u201393. https:\/\/doi.org\/10.1016\/j.ebiom.2015.02.014.","journal-title":"EBioMedicine"},{"key":"439_CR128","doi-asserted-by":"publisher","unstructured":"Ghosh S, Arshi MU, Ghosh S, Jana A, Jash M, Khan J, et al. Mitochondria-targeted engineered peptide promotes myogenesis, mitigates fibrosis, and reduces inflammation in duchenne muscular dystrophy by suppressing mitoROS-mediated NF-\u03baB activation. Eur J Med Chem. 2026;310. https:\/\/doi.org\/10.1016\/J.EJMECH.2026.118777.","DOI":"10.1016\/J.EJMECH.2026.118777"},{"key":"439_CR129","doi-asserted-by":"publisher","unstructured":"Ng SY, Mikhail AI, Mattina SR, Lesinski MA, Rebalka IA, Hamstra SI, et al. Direct AMPK Activation Confers Mutation-Independent Therapeutic Benefit in Duchenne Muscular Dystrophy. J Cachexia Sarcopenia Muscle. 2026;17. https:\/\/doi.org\/10.1002\/JCSM.70200.","DOI":"10.1002\/JCSM.70200"},{"key":"439_CR130","unstructured":"Emery AEH, Muntoni F. Duchenne muscular dystrophy. Oxford University Press; 2003. https:\/\/librarysearch.kcl.ac.uk\/discovery\/fulldisplay\/alma990005911910206881\/44KCL_INST:44KCL_INST. Accessed 1 Jul 2026."},{"key":"439_CR131","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/OXFORDJOURNALS.BMB.A072349","volume":"45","author":"LM Kunkel","year":"1989","unstructured":"Kunkel LM, Hoffman EP. Duchenne\/Becker muscular dystrophy: a short overview of the gene, the protein, and current diagnostics. Br Med Bull. 1989;45:630\u201343. https:\/\/doi.org\/10.1093\/OXFORDJOURNALS.BMB.A072349.","journal-title":"Br Med Bull"},{"key":"439_CR132","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/HMG\/11.9.1095","volume":"11","author":"LE Warner","year":"2002","unstructured":"Warner LE, DelloRusso CT, Crawford RW, Rybakova IN, Patel JR, Ervasti JM, et al. Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum Mol Genet. 2002;11:1095\u2013105. https:\/\/doi.org\/10.1093\/HMG\/11.9.1095.","journal-title":"Hum Mol Genet"},{"key":"439_CR133","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1093\/HMG\/10.24.2745","volume":"10","author":"GE Crawford","year":"2001","unstructured":"Crawford GE, Lu QL, Partridge TA, Chamberlain JS. Suppression of revertant fibers in mdx mice by expression of a functional dystrophin. Hum Mol Genet. 2001;10:2745\u201350. https:\/\/doi.org\/10.1093\/HMG\/10.24.2745.","journal-title":"Hum Mol Genet"},{"key":"439_CR134","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1093\/HMG\/DDR433","volume":"20","author":"LM Judge","year":"2011","unstructured":"Judge LM, Arnett ALH, Banks GB, Chamberlain JS. Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice. Hum Mol Genet. 2011;20:4978\u201390. https:\/\/doi.org\/10.1093\/HMG\/DDR433.","journal-title":"Hum Mol Genet"},{"key":"439_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nmd.2024.01.004","volume":"36","author":"S Krishna","year":"2024","unstructured":"Krishna S, Piepho AB, Lake DM, Cumby LR, Lortz KK, Lowe J, et al. Gene therapy delivered micro-dystrophins co-localize with transgenic utrophin in dystrophic skeletal muscle fibers. Neuromuscul Disord. 2024;36:1\u20135. https:\/\/doi.org\/10.1016\/j.nmd.2024.01.004.","journal-title":"Neuromuscul Disord"},{"key":"439_CR136","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ANA.410300414","volume":"30","author":"EP Hoffman","year":"1991","unstructured":"Hoffman EP, Garcia CA, Chamberlain JS, Angelini C, Lupski JR, Fenwick R. Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of Duchenne muscular dystrophy. Ann Neurol. 1991;30:605\u201310. https:\/\/doi.org\/10.1002\/ANA.410300414.","journal-title":"Ann Neurol"},{"key":"439_CR137","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.medj.2023.02.005","volume":"4","author":"S Gorokhova","year":"2023","unstructured":"Gorokhova S, Schessl J, Zou Y, Yang ML, Heydemann PT, Sufit RL, et al. Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin. Med. 2023;4:245\u2013e2513. https:\/\/doi.org\/10.1016\/j.medj.2023.02.005.","journal-title":"Med"},{"key":"439_CR138","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.omtm.2023.08.009","volume":"30","author":"AA Stephenson","year":"2023","unstructured":"Stephenson AA, Nicolau S, Vetter TA, Dufresne GP, Frair EC, Sarff JE, et al. CRISPR-Cas9 homology-independent targeted integration of exons 1\u201319 restores full-length dystrophin in mice. Mol Ther Methods Clin Dev. 2023;30:486\u201399. https:\/\/doi.org\/10.1016\/j.omtm.2023.08.009.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"439_CR139","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1126\/SCIENCE.ADP8179","volume":"386","author":"SR Lindley","year":"2024","unstructured":"Lindley SR, Venkata Subbaiah KC, Priyanka F, Poosala P, Ma Y, Jalinous L, et al. Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies. Science. 2024;386:762\u20137. https:\/\/doi.org\/10.1126\/SCIENCE.ADP8179.","journal-title":"Science"},{"key":"439_CR140","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/NM1085","volume":"10","author":"P Gregorevic","year":"2004","unstructured":"Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004;10:828\u201334. https:\/\/doi.org\/10.1038\/NM1085.","journal-title":"Nat Med"},{"key":"439_CR141","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","volume":"33","author":"BJ Byrne","year":"2025","unstructured":"Byrne BJ, Flanigan KM, Matesanz SE, Finkel RS, Waldrop MA, D\u2019Ambrosio ES, et al. Current clinical applications of AAV-mediated gene therapy. Mol Ther. 2025;33:2479\u2013516. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.045.","journal-title":"Mol Ther"},{"key":"439_CR142","doi-asserted-by":"publisher","unstructured":"Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial. Neurol Ther. 2026;15. https:\/\/doi.org\/10.1007\/S40120-025-00879-8.","DOI":"10.1007\/S40120-025-00879-8"},{"key":"439_CR143","doi-asserted-by":"publisher","unstructured":"Wolff JM, Capocci N, Atas E, Bharucha-Goebel DX, Brandsema JF, Butterfield RJ, et al. Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2025;54. https:\/\/doi.org\/10.1016\/j.nmd.2025.106208.","DOI":"10.1016\/j.nmd.2025.106208"},{"key":"439_CR144","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","volume":"184","author":"M Tabebordbar","year":"2021","unstructured":"Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184:4919\u2013e493822. https:\/\/doi.org\/10.1016\/j.cell.2021.08.028.","journal-title":"Cell"},{"key":"439_CR145","doi-asserted-by":"publisher","unstructured":"Weinmann J, Weis S, Sippel J, Tulalamba W, Remes A, El Andari J, et al. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun. 2020;11. https:\/\/doi.org\/10.1038\/S41467-020-19230-W.","DOI":"10.1038\/S41467-020-19230-W"},{"key":"439_CR146","doi-asserted-by":"publisher","unstructured":"El Andari J, Renaud-Gabardos E, Tulalamba W, Weinmann J, Mangin L, Hong Pham Q, et al. Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders. Sci Adv. 2022;8. https:\/\/doi.org\/10.1126\/SCIADV.ABN4704.","DOI":"10.1126\/SCIADV.ABN4704"},{"key":"439_CR147","unstructured":"Addressing unmet needs for inherited neuromuscular diseases | Novartis. https:\/\/www.novartis.com\/stories\/addressing-unmet-needs-inherited-neuromuscular-diseases. Accessed 1 Jul 2026."},{"key":"439_CR148","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.1038\/s41467-024-52002-4","volume":"15","author":"A Vu Hong","year":"2024","unstructured":"Vu Hong A, Suel L, Petat E, Dubois A, Le Brun PR, Guerchet N, et al. An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species. Nat Commun Nat. 2024;15:7965. https:\/\/doi.org\/10.1038\/s41467-024-52002-4.","journal-title":"Nat Commun Nat"},{"key":"439_CR149","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/MT.2009.253","volume":"18","author":"E Kimura","year":"2010","unstructured":"Kimura E, Li S, Gregorevic P, Fall BM, Chamberlain JS. Dystrophin Delivery to Muscles of mdx Mice Using Lentiviral Vectors Leads to Myogenic Progenitor Targeting and Stable Gene Expression. Mol Ther. 2010;18:206\u201313. https:\/\/doi.org\/10.1038\/MT.2009.253.","journal-title":"Mol Ther"},{"key":"439_CR150","doi-asserted-by":"publisher","unstructured":"Hindi SM, Petrany MJ, Greenfeld E, Focke LC, Cramer AAW, Whitt MA et al. Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery. bioRxiv. 2023; https:\/\/doi.org\/10.1101\/2023.03.17.533157.","DOI":"10.1101\/2023.03.17.533157"},{"key":"439_CR151","unstructured":"Publications | Avidity Biosciences. https:\/\/www.aviditybiosciences.com\/publications. Accessed 1 Jul 2026."},{"key":"439_CR152","unstructured":"Flanigan KM, Deconinck N, De Waele L, Laverty CG, Lee J, Mcmillan H, et al. Jul. Zeleciment Rostudirsen Significantly Increased Dystrophin Protein Levels and Led to Functional Improvement in Clinical Measures in the DELIVER Trial. https:\/\/www.dyne-tx.com\/wp-content\/uploads\/Flanigan_2026_MDA_DELIVER_REC_Oral.pdf. Accessed 1 2026."},{"key":"439_CR153","unstructured":"Non Viral Gene Therapy Companies. Trailblazing Genetic Medicine. https:\/\/www.myosanatherapeutics.com\/. Accessed 1 Jul 2026."},{"key":"439_CR154","unstructured":"ESGCT 32nd Annual Congress In collaboration with SETGYC Seville, Spain October 7\u201310. 2025 Abstracts, 2026; https:\/\/journals.sagepub.com\/doi\/10.1177\/10430342251395854. Accessed 1 Jul 2026."},{"key":"439_CR155","doi-asserted-by":"publisher","unstructured":"Tian Y, Liu Y, Tong Y, Huntoon K, Yang L, Shi J, et al. Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy. Nat Biomedical Eng 2026. 2026;1\u201315. https:\/\/doi.org\/10.1038\/s41551-026-01689-5.","DOI":"10.1038\/s41551-026-01689-5"},{"key":"439_CR156","unstructured":"Update. Jul : Spot Bio launches with $40\u00a0M to study non-viral gene therapy for muscular dystrophy. https:\/\/endpoints.news\/spot-bio-launches-with-40m-to-study-mrna-therapy-for-muscular-dystrophy\/. Accessed 1 2026."},{"key":"439_CR157","unstructured":"Entos Pharmaceuticals. Innovating Genetic Medicines. https:\/\/entospharma.com\/. Accessed 1 Jul 2026."},{"key":"439_CR158","unstructured":"Genetics in Medicine Impact Factor. Trends and Significance. https:\/\/sonothera.com\/science\/#publishedresearch. Accessed 1 Jul 2026."},{"key":"439_CR159","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMC2212912","volume":"388","author":"CG B\u00f6nnemann","year":"2023","unstructured":"B\u00f6nnemann CG, Belluscio BA, Braun S, Morris C, Singh T, Muntoni F. Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy. N Engl J Med. 2023;388:2294\u20136. https:\/\/doi.org\/10.1056\/NEJMC2212912.","journal-title":"N Engl J Med"},{"key":"439_CR160","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1006\/mthe.2001.0496","volume":"4","author":"D Hartigan-O\u2019Connor","year":"2001","unstructured":"Hartigan-O\u2019Connor D, Kirk CJ, Crawford R, Mul\u00e9 JJ, Chamberlain JS. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther. 2001;4:525\u201333. https:\/\/doi.org\/10.1006\/mthe.2001.0496.","journal-title":"Mol Ther"},{"key":"439_CR161","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ymthe.2024.03.016","volume":"32","author":"R Kaczmarek","year":"2024","unstructured":"Kaczmarek R, Samelson-Jones BJ, Herzog RW. Immune tolerance induction by hepatic gene transfer: First-in-human evidence. Mol Ther. 2024;32:863\u20134. https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.016.","journal-title":"Mol Ther"},{"key":"439_CR162","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/BLOOD-2014-07-588194","volume":"125","author":"JM Crudele","year":"2015","unstructured":"Crudele JM, Finn JD, Siner JI, Martin NB, Niemeyer GP, Zhou S, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood. 2015;125:1553\u201361. https:\/\/doi.org\/10.1182\/BLOOD-2014-07-588194.","journal-title":"Blood"},{"key":"439_CR163","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/mt.2008.149","volume":"16","author":"GL Odom","year":"2008","unstructured":"Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin\/Utrophin-deficient mice. Mol Ther. 2008;16:1539\u201345. https:\/\/doi.org\/10.1038\/mt.2008.149.","journal-title":"Mol Ther"},{"key":"439_CR164","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/S41591-019-0594-0","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Morales L, Malik AS, Mead AF, Greer CD, Mitchell MA, et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat Med. 2019;25:1505\u201311. https:\/\/doi.org\/10.1038\/S41591-019-0594-0.","journal-title":"Nat Med"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-026-00439-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-026-00439-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-026-00439-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:41:23Z","timestamp":1788766883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13395-026-00439-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":164,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1186\/s13395-026-00439-0","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JSC is an inventor on several patents covering micro-dystrophins, split inteins and muscle-restricted promoters. JSC also serves on the Scientific Advisory Boards and holds equity in Solid Biosciences, Kinea Bio, Myosana Therapeutics and Myogene Bio.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"34"}}